Drug Discovery– category –

BPI Technology Advances Targeted Protein Degradation — A Site-Specific Strategy to Accelerate Drug Discovery Introduction Targeted protein degradation (TPD) has emerged as a transformative strategy in drug discovery, offering a means to ...

CAR T-cell therapy has revolutionized blood cancer treatment but traditionally relies on an ex vivo process—extracting T cells from patients, genetically modifying them outside the body, expanding them, and reinfusing them. This manufact...

A U.S. research team is developing a novel combination therapy of antibody drugs that directly targets the underlying causes of allergic diseases. The strategy simultaneously blocks immunoglobulin E (IgE), a key driver of allergic reacti...

A U.S. research team has revealed that repeat expansions in the C9orf72 gene — a major cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) — induce dysfunction of the nuclear pore complex (NPC) in neurons. In C...

While CAR T cell therapies have shown success primarily in hematologic malignancies, new advances are emerging for gastrointestinal (GI) solid tumors such as colorectal, gastric, and esophageal cancers. U.S. research teams have reported ...

A U.S. research team has demonstrated the therapeutic potential of epigenetic editing — a strategy that regulates gene expression without altering the DNA or RNA sequence itself. Unlike conventional gene editing, this approach employs pr...